Switching first-line disease-modifying therapy for relapsing-remitting multiple sclerosis in non-responders: is it a successful strategy?

被引：0
|
作者：
Gajofatto, A. [1 ]
Bacchetti, P. [1 ]
Grimes, B. [1 ]
High, A. [1 ]
Moraes, C. [1 ]
Waubant, E. [1 ]
机构：
[1] Univ Calif San Diego, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [1] Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis
    Gajofatto, A.
    Bacchetti, P.
    Grimes, B.
    High, A.
    Waubant, E.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (01) : 50 - 58
  • [2] Predictors of Response to First-Line Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
    Castillo-Trivino, Tamara
    Gajofatto, Alberto
    Bacchetti, Peter
    Waubant, Emmanuelle
    NEUROLOGY, 2010, 74 (09) : A155 - A155
  • [3] Treatment patterns after lack of response to first-line disease-modifying therapy for relapsing-remitting multiple sclerosis
    Teter, B.
    Agashivala, N.
    Hashmonay, R.
    Weinstock-Guttman, B.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 93 - 93
  • [4] Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
    Rosenzweig, Tamara M.
    Hartman, Sarah
    MacKenzie, Elizabeth
    FORMULARY, 2010, 45 (08) : 252 - 262
  • [5] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [6] Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis
    Yano, Hajime
    Gonzalez, Cindy T.
    Healy, Brian C.
    Glanz, Bonnie I.
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 47
  • [7] Disease-modifying therapy in relapsing-remitting multiple sclerosis: efficacy is paramount
    Cristiano, E
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 3 - 7
  • [8] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
    Goldberg, Lawrence D.
    Edwards, Natalie C.
    Fincher, Contessa
    Doan, Quan V.
    Al-Sabbagh, Ahmad
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07): : 543 - 555
  • [9] Cost-utility of First-line Disease-modifying Treatments for Relapsing Remitting Multiple Sclerosis
    Soini, Erkki
    Joutseno, Jaana
    Sumelahti, Marja-Liisa
    CLINICAL THERAPEUTICS, 2017, 39 (03) : 537 - +
  • [10] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
12345